Drug intelligence / Profile preview

RP-32661

Development stage: Preclinical
Lead developer: Revere Pharmaceuticals
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

RP-32661 is a small molecule inhibitor targeting Rac1, a member of the Rac family of small GTPases. It is being developed by Revere Pharmaceuticals for the treatment of solid tumors, with primary indications including colorectal cancer and non-small cell lung cancer. The drug acts as an antineoplastic agent by inhibiting the activity of Rac1 GTP binding protein, which plays a key role in tumor cell migration, cytoskeletal rearrangement, and proliferation. As of March 2025, it remains in preclinical development with plans to file an IND application for solid tumors.

Other names: RP-32661RP32661RP 32661

Targets

RAC1 (Rac family small GTPase 1)

Beyond the preview

Go deeper on RP-32661.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RP-32661.

Explore the full profile